Article Sidebar

PDF
Date Published: 12/07/2023
Online Published: 12/07/2023
Abstract Views: 198
Views PDF: 175
DOI: https://doi.org/10.58490/ctump.2023i61.683
Issue
No. 61 (2023): HỘI NGHỊ THƯỜNG NIÊN HỌC VIÊN – SINH VIÊN NGHIÊN CỨU KHOA HỌC NĂM 2023
Section
Article
How to Cite
Nguyen , T. K. N., Tran, V. A., Huynh, T. A., & Pham, T. N. N. (2023). EVALUATING CYP2C19 GENE POLYMORPHISMS AND INFLAMMATORY CELL RATIOS IN PROGNOSIS MAJOR ADVERSE CARDIAC EVENTS IN ACUTE CORONARY SYNDROME. Cantho Journal of Medicine and Pharmacy, 61, 343-350. https://doi.org/10.58490/ctump.2023i61.683

EVALUATING CYP2C19 GENE POLYMORPHISMS AND INFLAMMATORY CELL RATIOS IN PROGNOSIS MAJOR ADVERSE CARDIAC EVENTS IN ACUTE CORONARY SYNDROME

Tran Khuong Nha Nguyen 1,, Viet An Tran1, Tuan An Huynh1, Thi Ngoc Nga Pham1
1 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Background: CYP2C19 gene polymorphisms and inflammatory cell ratios are promised to be new markers in prognosis MACE in acute coronary symdrome. Objectives: To evaluate the prognostic value of CYP2C19 gene polymorphisms and inflammatory cell ratios in acute coronary syndrome. Method: This is a prospective study conducted at Can Tho University of Medicine and Pharmacy hospital. We enrolled 49 ACS patients and collected CYP2C19 genotypes and inflammatory cell ratios. The incidence of major adverse cardiovascular diseases (MACEs) during follow-up were determined. Results: Percentage of LOF allele was 53,1%. During the follow-up period, 14 MACEs occurred. Kaplain Meier showed that the incident of MACE was higher in LOF allele carriers with no significant difference. NLR, PLR, MPVLR all had significant predictive value for MACE (p<0,05). Conclusion: CYP2C19 gene polymorphisms *2,*3 may increase the incident of MACE. NLR, PLR, MPVLR were proved to be easily, low cost calculated predictors of MACE in patients with ACS. 

Article Details

Keywords

CYP2C19, inflammatory cell ratios, prognosis, major adverse cardiac events, acute coronary syndrome

References

1. Bộ Y Tế. Hướng dẫn chẩn đoán và xử trí hội chứng mạch vành cấp. Nhà xuất bản Y học. 2019. 1-2.
2. Đào Văn Đôn. Nghiên cứu các yếu tố ảnh hưởng đến hiệu quả chống kết tập tiểu cầu của clopidogrel trong điều trị hội chứng mạch vành cấp. Đại học Dược Hà Nội. 2020. 121.
3. Mehta S. R., Yusuf S., Peters R. J., Bertrand M. E., Lewis B. S., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. The Lancet. 2001. 358(9281), 527-533, https://doi.org/10.1016/s0140-6736(01)05701-4.
4. Wiviott S. D., Braunwald E., Angiolillo D. J., Meisel S., Dalby A. J., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–Thrombolysis in Myocardial Infarction 38. Circulation. 2008. 118(16), 1626-1636, https://doi.org/10.1161/CIRCULATIONAHA.108.791061.
5. Trần Hòa. Nghiên cứu mối liên quan giữa kiểu gen giảm chức năng CYP2C19*2,*3 và tiên lượng ở bệnh nhân được can thiệp đặt stent động mạch vành có điều trị Clopidogrel. Đại học Y Dược TP. Hồ Chí Minh. 2020. 118.
6. Vũ Ngọc Trung. Nghiên cứu tần suất đa hình gen CYP2C19 và mối liên quan với kết quả điều trị chống ngưng tập tiểu cầu ở bệnh nhân hội chứng mạch vành cấp. Trường Đại học Y Hà Nội. 2021. 135.
7. Choi D.-H., Kobayashi Y., Nishi T., Kim H. K., Ki Y.-J., et al. Combination of mean platelet volume and neutrophil to lymphocyte ratio predicts long-term major adverse cardiovascular events after percutaneous coronary intervention. Angiology. 2019. 70(4), 345-351, https://doi.org/10.1177/0003319718768658.
8. Shumilah, A. M., Othman, A. M., Al-Madhagi, A. K. Accuracy of neutrophil to lymphocyte and monocyte to lymphocyte ratios as new inflammatory markers in acute coronary syndrome. BMC Cardiovascular Disorders. 2021. 21, 1-6, https://doi.org/10.1186/s12872-021-02236-7.
9. Gao X., Liu Y., Tian Y., Rao C., Shi F., et al. Prognostic value of peripheral blood inflammatory cell subsets in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Journal of International Medical Research. 2021. 49(4), 1-16, https://doi.org/10.1177/03000605211010059.
10. Li X.-T., Fang H., Li D., Xu F.-Q., Yang B., et al. Association of platelet to lymphocyte ratio with in-hospital major adverse cardiovascular events and the severity of coronary artery disease assessed by the Gensini score in patients with acute myocardial infarction. Chinese Medical Journal. 2020. 133(04), 415-423, https://doi.org/10.1097/CM9.0000000000000650.
11. Willim H., Sari K., Cipta H. Mean platelet volume-to-lymphocyte ratio as a predictor of no-reflow phenomenon and in-hospital mortality following primary percutaneous coronary intervention in patients with STEMI. European Heart Journal. 2021. 42(Supplement_1), 724-1368, https://doi.org/10.1093/eurheartj/ehab724.1368.